ReviewCancer immunology research2019
Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy.
Review in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1.JCEM case reports · 2026Article
- Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.The oncologist · 2025Article
- Endogenous thymic regeneration: restoring T cell production following injury.Nature reviews. Immunology · 2025Review
- Thymic Mimetic Cells: Evolutionarily Ancient Mirrors of the Periphery.Immunological reviews · 2025Review
- Transcript splicing optimizes the thymic self-antigen repertoire to suppress autoimmunity.The Journal of clinical investigation · 2024Article
- Bridging the divide: unveiling mutual immunological pathways of cancer and pregnancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus.Cytokine · 2022Article
- Thymus and autoimmunity.Seminars in immunopathology · 2021Review
- Absence of central tolerance in Aire-deficient mice synergizes with immune-checkpoint inhibition to enhance antitumor responses.Communications biology · 2020Article
- Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.Frontiers in immunology · 2020Review
- The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A major breakthrough in cancer treatment occurred with the development of strategies that overcome T-cell tolerance toward tumor cells. These approaches enhance antitumor immunity by overcoming mechanisms that are normally in place to prevent autoimmunity but simultaneously prevent rejection of tumor cells. Although tolerance mechanisms that restrict antitumor immunity take place both in the thymus and periphery, only immunotherapies that target peripheral tolerance mechanisms occurring outside of the thymus are currently available. We review here recent gains in our understanding of how thymic tolerance mediated by the a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.